What Is Brenzavvy®?

If you’ve been looking for therapies that support healthy aging, you may have come across SGLT2 Inhibitors like Brenzavvy®. But what is Brenzavvy®, and why are longevity researchers and patients alike praising its potential?

Though FDA approved to treat diabetes, scientists are realizing that Brenzavvy® may do more than simply lower blood sugar. In fact, SGLT2 medications like Brenzavvy® are gaining popularity for their potential to slow the aging process and reduce the risk of age-related disease.

Here, we’ll discuss what Brenzavvy® is, how it works, and why it’s gaining attention in longevity science.

Key Takeaways:

• Brenzavvy® (Bexagliflozin) is an FDA-approved SGLT2 Inhibitor that flushes excess glucose in urine
• By mimicking caloric restriction, Brenzavvy® may support heart health, brain health, and weight management
• Animal studies on SGLT2 Inhibitors show a 14% lifespan increase and up to 51% reduced all-cause mortality risk
• Brenzavvy® may also help clear senescent “zombie” cells, a leading driver of cellular aging

What Is Brenzavvy®?

Brenzavvy®, or Bexagliflozin, belongs to a class of medications called SGLT2 Inhibitors. First FDA approved in 2023, Brenzavvy® is a new kid in this class, sharing space with other SGLT2 options like Invokana® (Canagliflozin), which has been FDA approved since 2013.

Short for sodium-glucose co-transporter 2, SGLT2 is a protein that reabsorbs glucose back into the bloodstream. SGLT2 Inhibitors like Brenzavvy® block the SGLT2 protein, allowing that excess glucose to be flushed out in urine.

How Does Brenzavvy® Work?

Not all SGLT2 Inhibitors work exactly the same way, but they all share the same primary mechanism of action: flushing excess glucose in urine.

Normally, the kidneys filter glucose from the bloodstream into urine before reabsorbing it back into the body. Once reabsorbed, it’s used primarily to fuel cells. But excess glucose that isn’t used for fuel is left in the bloodstream, increasing insulin resistance and the risk of prediabetes.

Where SGLT2 acts like a straw to bring glucose back into the body, SGLT2 Inhibitors block that straw. This leaves up to 50-80g of excess sugar in urine, where it’s then flushed from the body.

The main result is lower, stable blood sugar levels. But healthy glucose levels also reduce the metabolic strain on the body. In turn, this may slow hallmarks of aging and reduce the risk of age-related disease.

Beyond the glucose effect, research suggests that SGLT2 Inhibitors may activate three well-studied longevity pathways: mTOR, AMPK, and SIRT1. These are the same cellular signaling networks associated with caloric restriction and extended lifespan in model organisms. By modulating these pathways, SGLT2 Inhibitors may support cellular repair, reduce metabolic waste, and encourage the kind of energy-efficient cell behavior that researchers associate with slower biological aging.

What Is the Longevity Potential of Brenzavvy®?

Research into SGLT2 Inhibitors shows they may help protect the body from the long-term wear and tear of excess glucose. In this way, they may potentially support broader aspects of longevity and healthy aging:

• Lifespan
  Though focused studies on Brenzavvy® are still ongoing, animal studies on SGLT2 Inhibitors have shown a 14% increase in lifespan.
• Inflammation and oxidative stress
  SGLT2 Inhibitors allow cells to use energy more efficiently, which may activate anti-inflammatory pathways and improve mitochondrial function, potentially decreasing oxidative stress and inflammation.
• Cardiovascular and kidney health
  Leaving excess glucose in urine reduces the afterload on the heart and kidneys, which may encourage less strain on these systems.
• Alzheimer’s and Parkinson’s risk
  Stable blood sugar could also improve blood flow to the brain, reducing risk factors of cognitive decline like hyperglycemia, insulin resistance, and amyloid plaque.
• Moderate weight loss
  Flushing excess glucose maintains a steady caloric deficit of up to an extra 360kcal per day, which may encourage moderate weight loss of up to 2-4% of total body weight.
• Senescent cell removal
  Senescent “zombie” cells are a leading driver of aging, caused by damaged cells that stop dividing, but won’t die. By activating anti-inflammatory pathways, SGLT2 Inhibitors like Brenzavvy® may help the body clear senescent cells.

Many of these pathways are tied to caloric restriction. In fact, SGLT2 Inhibitors mimic a state of caloric restriction by stabilizing glucose. Caloric restriction remains one of the best lifestyle factors tied to longevity. Separately, observational research on SGLT2 Inhibitors has found they may be associated with up to a 51% reduced risk of all-cause mortality, though this finding comes from a distinct study and does not establish a direct causal link to the caloric restriction mechanism.

Brenzavvy® for Longevity

As the research shows, Brenzavvy® has clear potential that goes far beyond diabetes care. By reducing metabolic strain, improving heart and kidney function, and even mimicking the effects of caloric restriction, Brenzavvy® may help protect against some of the most common drivers of aging.

What makes this particularly interesting for people without diabetes is that the mechanism does not depend on treating high blood sugar in a clinical sense. The body naturally absorbs glucose after every meal, and even in metabolically healthy adults, that daily glucose load creates cellular wear over decades. Brenzavvy® offsets a portion of that load by routing excess sugar out of the body before it can accumulate. Over time, that steady reduction in glucose exposure may translate into real biological benefits for anyone looking to protect their long-term health.

What Is Invokana®?

Invokana® (Canagliflozin) belongs to the same SGLT2 Inhibitor class as Brenzavvy®. Originally FDA approved to help manage blood sugar in adults with type 2 diabetes, research suggests Invokana® may also support heart and kidney health, even in people without diabetes. Like Brenzavvy®, Invokana® blocks the SGLT2 transporter in the kidneys, allowing excess glucose to be flushed out in urine instead of reabsorbed into the bloodstream.

Large clinical trials suggest Invokana® may lower the risk of cardiovascular death and reduce heart failure hospitalizations. It may also slow the progression of kidney disease in people with type 2 diabetes. Because Invokana® and Brenzavvy® share a similar mechanism, researchers have learned much about Invokana®’s broader health effects. These findings may help inform our understanding of newer SGLT2 Inhibitors like Brenzavvy® as well.

Invokana®’s decade-long track record also makes it a useful reference point for understanding tolerability. The most common side effects seen across SGLT2 Inhibitors include increased urination, mild dehydration, and a higher rate of urinary tract infections. These effects tend to reflect the mechanism at work, since the kidneys are actively excreting more glucose, rather than signs of a serious problem. For most people, they are manageable and tend to ease as the body adjusts.

Feature	Brenzavvy® (Bexagliflozin)	Invokana® (Canagliflozin)
FDA approval year	2023	2013
Primary mechanism	Blocks SGLT2 protein; flushes excess glucose in urine	Blocks SGLT2 protein; flushes excess glucose in urine
Cardiovascular benefit	Being studied	Associated with reduced risk of cardiovascular death and heart failure hospitalization
Kidney health	Being studied	Associated with slower kidney disease progression
Moderate weight support	Yes	Yes
Preclinical lifespan extension benefit	Being studied	Yes
Reduced all-cause mortality	Being studied	Yes
Available through AgelessRx	Yes	Yes

If you’re curious about adding Brenzavvy® to your longevity toolkit, AgelessRx makes it simple to get started. So why wait? You can get started with a free medical intake in less than 5 minutes. If approved, you can start Brenzavvy® in less than 2 weeks. With ongoing medical support from licensed experts, you’ll never have to wonder what’s next in your longevity journey. When you’re ready, get started with Brenzavvy® to see if it’s right for you.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.